Research Article

Adenylyl Cyclase Signaling in the Developing Chick Heart:
The Deranging Effect of Antiarrhythmic Drugs

Lucie Hejnova, Klara Hahnova, Radka Kockova, Jarmila Svatunkova, David Sedmera, and Jiri Novotny

1 Department of Physiology, Faculty of Science, Charles University in Prague, 128 43 Prague, Czech Republic
2 Institute of Physiology, Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic
3 Institute of Anatomy, First Faculty of Medicine, Charles University in Prague, 128 00 Prague, Czech Republic

Correspondence should be addressed to Jiri Novotny; jiri.novotny@natur.cuni.cz

Received 28 February 2014; Revised 14 May 2014; Accepted 29 May 2014; Published 23 June 2014

Academic Editor: Diego Franco

Copyright © 2014 Lucie Hejnova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The adenylyl cyclase (AC) signaling system plays a crucial role in the regulation of cardiac contractility. Here we analyzed the key components of myocardial AC signaling in the developing chick embryo and assessed the impact of selected $\beta$-blocking agents on this system. Application of metoprolol and carvedilol, two commonly used $\beta$-blockers, at embryonic day (ED) 8 significantly downregulated (by about 40%) expression levels of AC5, the dominant cardiac AC isoform, and the amount of Gs protein at ED9. Activity of AC stimulated by forskolin was also significantly reduced under these conditions. Interestingly, when administered at ED4, these drugs did not produce such profound changes in the myocardial AC signaling system, except for markedly increased expression of Gi protein. These data indicate that $\beta$-blocking agents can strongly derange AC signaling during the first half of embryonic heart development.

1. Introduction

Cardiovascular diseases represent frequent life-threatening health problems in the western society and they can also be encountered during pregnancy [1, 2]. It is evident that the need of expanded use of cardiac medication goes hand in hand with the increasing age of pregnant women. Nowadays, $\beta$-blockers are the most commonly used agents for treatment of arrhythmias, ischemic heart disease, heart failure, and hypertension [3]. Nevertheless, there is only sparse information concerning potential harmful effects of the $\beta$-blockers on fetal development and child health when used in pregnancy. Some recent findings indicate that children of mothers treated with $\beta$-blockers during pregnancy may be at higher risk for cardiovascular defects [4–6]. However, the embryotoxic mechanisms of these compounds are still not well understood.

The chick embryonic heart has proven to be a good model for studying developmental physiology of the cardiovascular system and it can also be useful for exploring cardiotoxicity of catecholamines and $\beta$-blocking agents [7]. In the chick embryo, the onset of sympathetic cardiac innervation occurs at about embryonic day (ED) 9 and this system is functional by ED16 [8]. During subsequent stages of development, the number of myocardial $\beta$-adrenergic receptors increases, reaching adult values on postnatal day 7 [9]. However, autonomic receptor-mediated effector mechanisms seem to be present in the heart before there is functional innervation. The ability of exogenous noradrenaline to elicit acceleration of heart rate has been observed already in the early stages of chick embryo development [10]. Interestingly, the preneural period of heart development is characterized by the presence of relatively high levels of catecholamines, which may be secreted by the developing adrenal medulla or sympathetic chain ganglia [11, 12].

Some early experiments with catecholamines and $\beta$-blockers revealed that the chick heart is more resistant to these drugs in early embryonic stages than in later stages of prenatal development [13]. Our previous study focused on determining the effect of metoprolol and carvedilol, two
β-blockers frequently used in clinical practice, indicated that administration of these drugs at ED8 may cause much more pronounced decrease in heart rate when compared to treatment at ED4 [14]. Interestingly, this effect was mediated by lower number of β-adrenergic receptors (β-ARs) in older chick embryos. In contrast to metoprolol, carvedilol lowered the number of myocardial β-ARs, but metoprolol reduced heart rate more effectively than carvedilol [14]. It is well known that β-ARs receptors transfer information through their cognate G proteins to adenylyl cyclase (AC), and this signaling system is crucially involved in the regulation of cardiac function [15, 16]. The main aim of our present work was to characterize the major components of the chick myocardial AC signaling system during embryonic development and to assess the potential impact of β-blockers on its function.

2. Materials and Methods

2.1. Materials. [α-32P]ATP was purchased from Izotop (Budapest, Hungary), [3H]cAMP from ARC (St. Louis, MO, USA), and scintillation cocktail EcoLite from MP Biochemicals (Santa Ana, CA, USA). Acrylamide and bisacrylamide were from SERVA (Heidelberg, Germany), and aluminum oxide 90 (neutral, activity I) was from Merck (Darmstadt, Germany). All other chemicals were from Sigma (St. Louis, MO, USA) and they were of the highest purity available. AC5 antibody was from Abcam (Cambridge, UK) and Gsα and actin antibodies were from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Preparation and characterization of Gsα(1,2) antibody were described previously [17].

2.2. Chick Embryo Incubation and Drug Application. Fertilized white Leghorn chicken eggs were incubated with their blunt end up in forced draft incubator at 38°C and 75% humidity up to embryonic days (ED) 4–18. The eggs were turned automatically every 4 h. At ED4 or ED8 or ED4 + ED8, 200 μL metoprolol (1 mg/mL) or 50 μL carvedilol (1 mg/mL) dissolved in normal saline was administered intra-amniotically through a small opening made in the egg shell. More specifically, the eggs were divided into seven groups. Whereas the first group received metoprolol and the second group carvedilol at ED4, the third and fourth group received, respectively, metoprolol and carvedilol only at ED8. The fifth group received metoprolol at both ED4 and ED8 (ED4 + ED8), and the sixth group received carvedilol at both ED4 and ED8 (ED4 + ED8). Normal saline was administered to the seventh group (control, ED9) at both ED4 and ED8. After finishing injecting, all the eggs were sealed and further incubated until ED9.

2.3. Preparation of Crude Membranes. Chick hearts (normal at various developmental stages and ED9 with and without treatment with beta-blockers at ED4, ED8, and ED4 + ED8) were homogenized in TMES buffer containing 20 mM Tris-HCl, 3 mM MgCl2, 1 mM EDTA, and 250 mM sucrose (pH 7.4) supplemented with protease inhibitor cocktail (Roche Diagnostics), using Potter-Elvehjem glass-teflon homogenizer on ice. Coarse cell debris and nuclei were removed by low-speed centrifugation (600 g, 10 min, 4°C), and membranes were then pelleted by centrifugation at 50,000 g for 30 min at 4°C. The pellets were resuspended in TME buffer (20 mM Tris-HCl, 3 mM MgCl2, and 1 mM EDTA; pH 7.4), aliquoted into Eppendorf tubes, snap-frozen in liquid nitrogen, and stored at −80°C.

2.4. Assessment of Adenylyl Cyclase Activity. Adenylyl cyclase (AC) activity in myocardial membranes was determined by measuring the conversion of [α-32P]ATP to [32P]cAMP according to the method of Salomon et al. [18]. Myocardial membranes (20 μg of proteins) were incubated in the reaction mixture (100 μL) containing 48 mM Tris- HCl buffer (pH 7.4), 100 mM NaCl, 2 mM MgCl2, 20 μM GTP, 0.8 mg/mL BSA, 5 mM phosphoenolpyruvate, 3.2 U of pyruvate kinase, 40 μM 3-isobutyl-1-methylxanthine, 0.1 mM cAMP, and about 10,000 cpm [3H]cAMP as a tracer. Stimulated AC activity was measured after addition of 10 μM isoprenaline or 10 μM forskolin. After 1 minute preincubation 0.4 mM ATP was added along with 200,000 cpm [α-32P]ATP and incubation proceeded for 20 min at 30°C. The reaction was stopped by addition of 200 μL 0.5 M HCl and heating at 100°C for 5 min. Samples were neutralized by 200 μL 1.5 M imidazole. Separation of newly formed [32P]cAMP was performed by using dry alumina column chromatography as described by White [19]. Column recovery was usually about 70–75%.

2.5. Electrophoresis and Western Blotting. Samples of myocardial membranes were solubilized in Laemmli buffer and loaded (30 μg per lane) on standard 10% acrylamide gels for SDS-PAGE. After electrophoresis, the resolved proteins were transferred to nitrocellulose membrane (Schleicher & Schuell), blocked with 5% nonfat dry milk in TBS buffer (10 mM Tris and 150 mM NaCl; pH 8.0) for 1 h, and then incubated with relevant primary antibodies overnight at 4°C. After three 10 min washes in TBS containing 0.3% Tween 20, the secondary anti-rabbit IgG labeled with horseradish peroxidase was applied for 1 h at room temperature. After another three 10 min washes in TBS-Tween, the blots were visualized by enhanced chemiluminescence technique according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL, USA). To ensure equal protein loading on the gel, the membranes were stripped and reprobed with actin antibody. The immunoblots were scanned and quantitatively analyzed by ImageQuant TL software (Amersham Biosciences). Relative expression levels of AC5, Gsα, and Gαi were always normalized to the corresponding expression of actin.

3. Results

3.1. Adenylyl Cyclase Activity. Activity of AC in myocardial preparations from chick embryos did not significantly differ between ED4 and ED8 (Figure 1). Whereas the β-adrenergic agonist isoprenaline increased the basal AC activity by about
3.2 Developmental Expression of Adenylyl Cyclase and G Proteins. The distribution of AC5 and α subunits of the stimulatory (Gs) and inhibitory (Gi) G proteins as the key components of the AC signaling system was determined in myocardial preparations from different developmental stages of the chick embryo. The expression level of the dominant cardiac AC isoform, AC5, slightly increased during early stages of embryonic development, but it fell by over 30% between ED12 and ED18. Whereas AC5 expression was not affected by metoprolol or carvedilol at ED4, administration of these drugs at ED8 resulted in a marked decrease (by about 50%) in cardiac AC5 (Figure 4). When applied at ED4 + ED8, the β-blockers also reduced AC5 levels, but to a much lesser extent (by about 20%).

Immunohistochemical assessment of the developmental profile of selected G protein subunits indicated relatively very low expression levels of the α subunits of Gs and Gi proteins in the earliest stages of heart development and these levels increased dramatically between ED4 and ED8 (Figure 3).

Thereafter, the expression of G protein α subunits remained relatively unchanged until ED18. When applied on ED4, metoprolol and carvedilol did not significantly affect Gsα levels in the developing chick heart (Figure 4). However, injection of metoprolol at ED8 and ED4 + ED8 led to a decline (by about 40–60%) in Gsα expression. Interestingly, no such effects were observed after treatment with carvedilol. By contrast, carvedilol applied at ED4 + ED8 increased Gsα expression by about 30%. Application of both β-blockers at ED4 and application of carvedilol at ED8 or ED4 + ED8 markedly increased (by about 60%) the amount of Gα× at ED9 (Figure 4). Treatment of chick embryos with metoprolol at ED8 or ED4 + ED8 did not elicit such profound changes in the content of myocardial Gα× protein.

4. Discussion

Heart function can be favorably modulated by β-blocking agents under some pathological conditions. However, there is also some evidence that these drugs may be potentially harmful to embryonic or fetal development when administered during pregnancy. In the present work we set to evaluate the impact of two widely used β-blockers, namely, metoprolol and carvedilol, on the key components and function of the myocardial adenylyl cyclase signaling system in the developing chick embryo.

40–45%, forskolin, a direct activator of the AC catalytic subunit and Gs protein, augmented the enzyme activity up to 10-fold. However, the extent of the stimulatory effects of both of these activators did not significantly differ between samples prepared from different developmental stages of the chick embryo. It is worth noting that there was a slight downward tendency in isoprenaline-stimulated AC activity in the later stages of embryonic development.

In the next series of experiments we investigated the impact of β-blockers applied during early developmental stages on myocardial AC activity assessed at ED9. Neither metoprolol nor carvedilol injected into the developing chick embryos at ED4 or ED4 + ED8 altered AC activity at ED9 but both of these drugs significantly suppressed forskolin-stimulated AC activity when administered at ED8 (Figure 2).

Thereafter, the expression of G protein α subunits remained relatively unchanged until ED18. When applied on ED4, metoprolol and carvedilol did not significantly affect Gsα levels in the developing chick heart (Figure 4). However, injection of metoprolol at ED8 and ED4 + ED8 led to a decline (by about 40–60%) in Gsα expression. Interestingly, no such effects were observed after treatment with carvedilol. By contrast, carvedilol applied at ED4 + ED8 increased Gsα expression by about 30%. Application of both β-blockers at ED4 and application of carvedilol at ED8 or ED4 + ED8 markedly increased (by about 60%) the amount of Gα× at ED9 (Figure 4). Treatment of chick embryos with metoprolol at ED8 or ED4 + ED8 did not elicit such profound changes in the content of myocardial Gα× protein.

4. Discussion

Heart function can be favorably modulated by β-blocking agents under some pathological conditions. However, there is also some evidence that these drugs may be potentially harmful to embryonic or fetal development when administered during pregnancy. In the present work we set to evaluate the impact of two widely used β-blockers, namely, metoprolol and carvedilol, on the key components and function of the myocardial adenylyl cyclase signaling system in the developing chick embryo.
**Figure 3**: Expression of adenylyl cyclase and G protein subunits in the developing chick heart. Proteins from myocardial membrane preparations derived from different developmental stages of the chick embryo were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with specific antibodies to AC5 isoform and α subunits of Gs and Gi(1,2) proteins. After stripping, the membranes were reprobed with actin antibody to control for differences in protein loading. Representative blots are shown, each of three independently performed experiments (a) and the graphical representation of relative expression levels (means ± SEM) of AC5, Gsα, and Giα normalized to the corresponding expression of actin (b). * Indicates significantly different expression of the individual proteins in samples from ED8, ED12, and ED18 as compared to ED4 (P < 0.05).

**Figure 4**: Effect of β-blockers on expression of adenylyl cyclase and G protein subunits in the chick embryonic heart. Samples of myocardial membrane proteins prepared from ED9 chick embryos, both control (CON) and previously treated with metoprolol (Met) or carvedilol (Car) at ED4, ED8, or ED4 + ED8, were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with specific antibodies to AC5 isoform and α subunits of Gs and Gi(1,2) proteins. After stripping, the membranes were reprobed with actin antibody to control for differences in protein loading. Representative blots are shown, each of three independently performed experiments (a) and the graphical representation of relative expression levels (means ± SEM) of AC5, Gsα, and Giα normalized to the corresponding expression of actin (b). * Indicates a statistically significant difference between the indicated group affected by β-blockers and control (P < 0.05).
Our current experimental results have indicated that, despite a perceptible decrease in the amount of the predominant isoform of cardiac adenylyl cyclase (AC5) between ED12 and ED18, the enzyme activity of AC is relatively stable in the course of chick embryo development, which is in line with some earlier findings [20, 21]. In parallel, rather incongruently, there was a marked increase in G5 and G1 protein levels between ED4 and ED8. However, a similar rise in myocardial G1 during the early development of the chick embryo was reported also by others [21]. Results of our previous study and some other studies indicated that partial loss of myocardial + ARs in the embryonic tissues fails to produce desensitization in adulthood, agonist-induced stimulation of β-ARs in the embryonic tissues fails to produce desensitization, and instead responsiveness increases. The peculiar regulatory mechanisms, which may include adaptive changes at the level of the receptors, G proteins, and AC, are instrumental for the necessary physiological adjustments during prenatal life and preparation for the postpartum period. It has become clear that there are unique developmental stages of susceptibility between species and embryonic exposure to harmful substances may lead to impairment of cardiac development and function [13, 29–32]. Our current research has revealed that application of the β-blockers metoprolol and carvedilol to the chick embryo during the first half of prenatal development can markedly derange myocardial β-ARs-mediated AC signaling. We have observed that β-blockers, which are used for their antiarrhythmic effects, may not always be beneficial but they can also affect the expression of myocardial β-ARs, G proteins, and AC as well as the function of this important signaling system during embryonic development. Therefore, physicians should be aware of potentially harmful side effects when prescribing these drugs during pregnancy.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

This study was supported by the Charles University Grant Agency (610612), the Ministry of Education, Youth and Sport of the Czech Republic (SVV-260087/2014), and PRVOUK (P35/LF1/5). Further support by the Academy of Sciences (RVO: 67985823) and Grant Agency of the Czech Republic (P302/11/1308) is gratefully acknowledged.

**References**

[1] S. Nanda, C. Nelson-Piercy, and L. Mackillop, “Cardiac disease in pregnancy,” *Clinical Medicine, Journal of the Royal College of Physicians of London*, vol. 12, no. 6, pp. 553–560, 2012.

[2] M. A. Nickens, R. C. Long, and S. A. Geraci, “Cardiovascular disease in pregnancy (Women’s Health Series),” *Southern Medical Journal*, vol. 106, no. 11, pp. 624–630, 2013.

[3] W. H. Frishman, “β-adrenergic blockade in cardiovascular disease,” *Journal of Cardiovascular Pharmacology and Therapeutics*, vol. 18, no. 4, pp. 310–319, 2013.

[4] A. R. Caton, E. M. Bell, C. M. Druschel et al., “Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations,” *Hypertension*, vol. 54, no. 1, pp. 63–70, 2009.

[5] C. Vasilikis-Scaramozza, A. Aschengrau, H. J. Cabral, and S. S. Jick, “Antihypertensive drugs and the risk of congenital anomalies,” *Pharmacotherapy*, vol. 33, no. 5, pp. 476–482, 2013.

[6] M. Y. Yakoob, B. T. Bateman, E. Ho et al., “The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis,” *Hypertension*, vol. 62, no. 2, pp. 375–381, 2013.

[7] K. Ruijtenbeek, J. G. R. De Mey, C. E. Blanco, and H. Ehmke, “The chicken embryo in developmental physiology of the cardiovascular system: A traditional model with new possibilities,” *American Journal of Physiology: Regulatory Integrative and Comparative Physiology*, vol. 283, no. 2, pp. R549–R551, 2002.

[8] M. L. Kirby, “Innervation of the developing heart,” in *Cardiac Development*, pp. 179–197, Oxford University Press, 2007.

[9] D. Higgins and A. J. Pappano, “A histochemical study of the ontogeny of catecholamine-containing axons in the chick embryo heart,” *Journal of Molecular and Cellular Cardiology*, vol. 11, no. 7, pp. 661–668, 1979.
[10] N. G. Culver and D. A. Fischman, “Pharmacological analysis of sympathetic function in the embryonic chick heart,” The American Journal of Physiology, vol. 232, no. 3, pp. RI16–RI23, 1977.

[11] D. E. Stewart and M. L. Kirby, “Endogenous tyrosine hydroxylase activity in the developing chick heart: a possible source of extraneuronal catecholamines,” Journal of Molecular and Cellular Cardiology, vol. 17, no. 4, pp. 389–398, 1985.

[12] A. L. M. Mulder, J. M. C. G. van Golde, A. A. C. van Goor, D. A. Giussani, and C. E. Blanco, “Developmental changes in plasma catecholamine concentrations during normoxia and acute hypoxia in the chick embryo,” Journal of Physiology, vol. 527, no. 3, pp. 593–599, 2000.

[13] S. Zamenhof, “Selective sensitive period in chick embryo: toxic effect of exogenous neurotransmitters,” Cytobios, vol. 58, no. 234-235, pp. 171–177, 1989.

[14] R. Kockova, J. Svatunkova, J. Novotny, L. Hejnova, B. Ostadal, and D. Sedmera, “Heart rate changes mediate the embryotoxic effect of antiarrhythmic drugs in the chick embryo,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 304, no. 6, pp. H595–H902, 2013.

[15] D. E. Vatner, K. Asai, M. Iwase et al., “Beta-adrenergic receptor-G protein-adenyl cyclase signal transduction in the failing heart,” American Journal of Cardiology, vol. 83, no. 12, pp. 80H–85H, 1999.

[16] S. B. Wachter and E. M. Gilbert, “Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application,” Cardiology, vol. 122, no. 2, pp. 104–112, 2012.

[17] J. Novotny, L. Bouřová, F. Kolář, and P. Svoboda, “Membrane-bound and cytosolic forms of heterotrimeric G proteins in young and adult rat myocardium: influence of neonatal hypoxia and hyperthyroidism,” Journal of Cellular Biochemistry, vol. 82, no. 2, pp. 215–224, 2001.

[18] Y. Salomon, C. Londos, and M. Rodbell, “A highly sensitive adenylate cyclase assay,” Analytical Biochemistry, vol. 58, no. 2, pp. 541–548, 1974.

[19] A. A. White, “Separation and purification of cyclic nucleotides by alumina column chromatography,” Methods in Enzymology, vol. 38, pp. 41–46, 1974.

[20] R. W. Alexander, J. B. Galper, E. J. Neer, and T. W. Smith, “Non-co-ordinate development of β-adrenergic receptors and adenylate cyclase in chick heart,” Biochemical Journal, vol. 204, no. 3, pp. 825–830, 1982.

[21] S. W. Halvorsen and N. M. Nathanson, “Ontogenesis of physiological responsiveness and guanine nucleotide sensitivity of cardiac muscarinic receptors during chick embryonic development,” Biochemistry, vol. 23, no. 24, pp. 5813–5821, 1984.

[22] M. T. Phillips, M. L. Kirby, and D. E. Stewart, “Cyclic AMP in normal and sympathetically aural chick hearts during development,” Journal of Molecular and Cellular Cardiology, vol. 18, no. 8, pp. 827–835, 1986.

[23] D. E. Stewart, M. L. Kirby, and R. S. Aronstam, “Regulation of β-adrenergic receptor density in the non-innervated and denervated embryonic chick heart,” Journal of Molecular and Cellular Cardiology, vol. 18, no. 5, pp. 469–475, 1986.

[24] L. Brown, N. M. Deighton, S. Bals et al., “Spare receptors for β-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart,” Journal of Cardiovascular Pharmacology, vol. 19, no. 2, pp. 222–232, 1992.

[25] D. A. Jackson and N. M. Nathanson, “Subtype-specific regulation of muscarinic receptor expression and function by heterologous receptor activation,” Journal of Biological Chemistry, vol. 270, no. 38, pp. 22374–22377, 1995.

[26] S. Dhein, P. Röhnter, S. Markau et al., “Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats,” Journal of the American College of Cardiology, vol. 36, no. 2, pp. 608–617, 2000.

[27] A. A. Alousi, J. R. Jasper, P. A. Insel, and H. J. Motulsky, “Stoichiometry of receptor-GS-adenylate cyclase interactions,” The FASEB Journal, vol. 5, no. 9, pp. 2300–2303, 1991.

[28] T. A. Slotkin, J. T. Auman, and F. J. Seidler, “Ontogenesis of β-adrenoceptor signaling: Implications for perinatal physiology and for fetal effects of tocolytic drugs,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 1, pp. 1–7, 2003.

[29] L. Venturini and S. B. Sparber, “Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis,” Free Radical Biology and Medicine, vol. 30, no. 2, pp. 198–207, 2001.

[30] M. C. Garofolo, F. J. Seidler, M. M. Cousins, C. A. Tate, D. Qiao, and T. A. Slotkin, “Developmental toxicity of terbutaline: critical periods for sex-selective effects on macromolecules and DNA synthesis in rat brain, heart, and liver,” Brain Research Bulletin, vol. 59, no. 4, pp. 319–329, 2003.

[31] A. L. Portbury, R. Chandra, M. Groelle et al., “Catecholamines act via a β-adrenergic receptor to maintain fetal heart rate and survival,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 284, no. 6, pp. H2069–H2077, 2003.

[32] V. J. Drake, S. L. Koprowski, N. Hu, S. M. Smith, and J. Lough, “Cardiogenic effects of trichloroethylene and trichloroacetic acid following exposure during heart specification of avian development,” Toxicological Sciences, vol. 94, no. 1, pp. 153–162, 2006.